Titan Pharmaceuticals Inc
NASDAQ:TTNP

Watchlist Manager
Titan Pharmaceuticals Inc Logo
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Watchlist
Price: 5.1 USD -1.54% Market Closed
Market Cap: 6.8m USD

EV/EBITDA
Enterprise Value to EBITDA

-0.9
Current
-0.6
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.9
=
Enterprise Value
4m USD
/
EBITDA
-4.6m USD
EBITDA Growth EV/EBITDA to Growth
US
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Average EV/EBITDA: 434.1
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.5
30%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.4
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.6
10%
11.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
13%
0.8
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A